Hexokinase as a Central Hub in Neurodegeneration: From Metabolic Dysfunction to Therapeutic Innovation
aging and disease · 2025
DOI: 10.14336/ad.2025.0891 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift aging and disease, 2025. Verfasst von Shiyuan Cai und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The People's Hospital of Miyi County, Panzhihua 617000, Sichuan, China. Hauptthemen laut MEDLINE: Neurodegenerative Diseases, Hexokinase. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, The People's Hospital of Miyi County, Panzhihua 617000, Sichuan, China.
- Department of Urology, The People's Hospital of Miyi County, Panzhihua 617000, Sichuan, China.
- Key Laboratory of Structure-Specific Small Molecule Drugs at Chengdu Medical College of Sichuan Province, School of Pharmacy, Chengdu Medical College, Chengdu.610500, Sichuan, China.
Zitieren
APA
Cai, S., Liu, Y., Liu, B., Liao, H., & Li, K. (2025). Hexokinase as a Central Hub in Neurodegeneration: From Metabolic Dysfunction to Therapeutic Innovation. aging and disease. https://doi.org/10.14336/ad.2025.0891
Vancouver
Cai S, Liu Y, Liu B, Liao H, Li K. Hexokinase as a Central Hub in Neurodegeneration: From Metabolic Dysfunction to Therapeutic Innovation. aging and disease. 2025. doi:10.14336/ad.2025.0891
BibTeX
@article{Cai2025,
author = {Cai, Shiyuan and Liu, Yanjun and Liu, Bo and Liao, Hongli and Li, Ke},
title = {Hexokinase as a Central Hub in Neurodegeneration: From Metabolic Dysfunction to Therapeutic Innovation},
journal = {aging and disease},
year = {2025},
doi = {10.14336/ad.2025.0891}
}
EUVIMED